Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $41.64 in the last session, up 1.44% from day before closing price of $41.05. In other words, the price has increased by $1.44 from its previous closing price. On the day, 1.74 million shares were traded. IONS stock price reached its highest trading level at $41.76 during the session, while it also had its lowest trading level at $40.86.
Ratios:
We take a closer look at IONS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 3.13 whereas as Long-Term Debt/Eq ratio is at 2.11.
On July 01, 2025, Barclays Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $57.
On April 07, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $45.H.C. Wainwright initiated its Buy rating on April 07, 2025, with a $45 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 06 ’25 when PARSHALL B LYNNE sold 5,000 shares for $41.93 per share. The transaction valued at 209,646 led to the insider holds 86,344 shares of the business.
Geary Richard S sold 10,000 shares of IONS for $428,593 on Aug 05 ’25. The EVP, Chief Development Officer now owns 89,492 shares after completing the transaction at $42.86 per share. On Aug 06 ’25, another insider, PARSHALL B LYNNE, who serves as the Officer of the company, bought 10,000 shares for $41.93 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 6637041664 and an Enterprise Value of 6328083968. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.03 while its Price-to-Book (P/B) ratio in mrq is 10.49. Its current Enterprise Value per Revenue stands at 6.703 whereas that against EBITDA is -24.799.
Stock Price History:
The Beta on a monthly basis for IONS is 0.28, which has changed by -0.11517215 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $50.43, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 4.90%, while the 200-Day Moving Average is calculated to be 18.50%.
Shares Statistics:
According to the various share statistics, IONS traded on average about 1.78M shares per day over the past 3-months and 2528020 shares per day over the past 10 days. A total of 159.20M shares are outstanding, with a floating share count of 155.53M. Insiders hold about 2.44% of the company’s shares, while institutions hold 104.24% stake in the company. Shares short for IONS as of 1752537600 were 12889193 with a Short Ratio of 7.22, compared to 1749772800 on 14225565. Therefore, it implies a Short% of Shares Outstanding of 12889193 and a Short% of Float of 10.75.
Earnings Estimates
The current rating of Ionis Pharmaceuticals Inc (IONS) is the result of assessments by 7.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.67 and low estimates of -$1.15.
Analysts are recommending an EPS of between -$1.6 and -$2.58 for the fiscal current year, implying an average EPS of -$1.98. EPS for the following year is -$1.7, with 12.0 analysts recommending between $0.25 and -$3.68.
Revenue Estimates
According to 15 analysts, the current quarter’s revenue is expected to be $131.91M. It ranges from a high estimate of $172.55M to a low estimate of $111.1M. As of the current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $134MFor the next quarter, 15 analysts are estimating revenue of $148.67M. There is a high estimate of $218M for the next quarter, whereas the lowest estimate is $131M.
A total of 22 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $961.6M, while the lowest revenue estimate was $837.85M, resulting in an average revenue estimate of $869.49M. In the same quarter a year ago, actual revenue was $705MBased on 25 analysts’ estimates, the company’s revenue will be $909.59M in the next fiscal year. The high estimate is $1.35B and the low estimate is $620.82M.
